Calcium pyrophosphate disease and polymyalgia rheumatica: association or coincidence? Comment on “Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica” Ottaviani et al.

Sirs,

We read with interest the article “Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica”, recently published in Clinical and Experimental Rheumatology (1). Among the 52 enrolled patients fulfilling the 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for polymyalgia rheumatica (PMR) (2), Ottaviani et al. identified 25 (48.07%) with a diagnosis of calcium pyrophosphate disease (CPPD). The authors concluded that EU-LAR/ACR criteria do not allow excluding CPPD as PMR-mimicking disease, because all patients affected with CPPD fulfilled these same classification criteria. They also proposed that expanding ultrasound (US) examination in patients with suspected PMR should be considered.

In a clinical practice, determining whether patient suffers from PMR or CPPD is not always easy, and the possibility that one condition could be the trigger factor for the other cannot be excluded. Our 59-year-old female patient was diagnosed with PMR, presenting classical manifestations, fulfilling the 2012 EULAR/ACR classification criteria, after exclusion of rheumatoid arthritis and connective tissue diseases. Good control of PMR enabled gradual withdrawal of GCs within one year. However, in the next 9 years she developed two episodes of effusive knee joint arthritis. Knee joint ultrasound showed prominent synovitis and cartilage calcifications. Joint fluid aspirate showed the presence of positively birefringent CPP crystals by polarised light microscopy. Colchicine 1mg per day brought resolution of symptoms, however without normalising of CRP. After three further months, she complained of arm and pelvic girdle pain with general malaise. Induction of low dose CS brought fast and complete resolution of her symptoms.

The second question is: what is the value of US examination of AC joints in distinguishing CPPD from PMR? To answer this question, we re-evaluated a bi-centric US database of confirmed PMR cases according to US CPPD criteria proposed by Ottaviani et al. All examinations were performed between 2014 and 2020 using a predefined protocol based on protocols by Jiménez-Palop et al. (7) and Falsetti et al. (8). Among 204 patients with 208 pictures of AC joints (minimum one picture for patient available), we identified only one case meeting these criteria, and further 22 possible, however doubtful pictures. No diagnosis of CPPD had previously been made in these patients.

In conclusion, we are grateful to Ottaviani et al. for allowing us to critically revise our clinical perspective (9, 10). We agree that the possibility of underestimated CPPD should be considered at every stage of PMR. We also agree that expanding standard shoulder examination in PMR patients to include AC joints might be of clinical relevance. However, the question remains whether to consider PMR and CPPD accompanying or randomly associated diseases.

Informed consent: all patients gave their informed consent in line with the specific national provisions.

M. MILCHERT1, MD, PhD
C. MANZO2, MD
A. CASTAGNA3, MD, PhD
M. BRZOSKO4, MD, Prof.

1Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Poland; 2Azienda Sanitaria Locale Napoli 3 sud., Internal and Geriatric Medicine Department; Rheumatologic Outpatient Clinic, Health District no. 59, Sant’Agnello, Naples, Italy; 3Azienda Sanitaria Provinciale Catanzauro, Primary Care Department, Fragility Outpatient Clinic, Casa della salute Chiaravalle Centrale, Chiaravalle, Cutrofiano, Italy.

Please address correspondence to: Ciro Manzo,
Rheumatology Outpatient Clinic, Poliambulatorio Mariano Lauro, via dei Pini, 80065 Sant’Agnello (NA), Italy.
E-mail: manzoreumatologo@libero.it
ORCID: 0000-0002-4800-1817
Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2021.

References